Cingulate Financials
| CING Stock | USD 5.04 0.16 3.28% |
Cingulate Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.78 | 2.93 |
|
|
Investors should never underestimate Cingulate's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cingulate's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cingulate.
Net Income |
|
Cingulate | Select Account or Indicator | Build AI portfolio with Cingulate Stock |
Understanding current and past Cingulate Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cingulate's financial statements are interrelated, with each one affecting the others. For example, an increase in Cingulate's assets may result in an increase in income on the income statement.
Cingulate Stock Summary
Cingulate competes with Allarity Therapeutics, Lexaria Bioscience, Lixte Biotechnology, Kairos Pharma, and Synlogic. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US17248W3034 |
| Business Address | 1901 West 47th |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cingulate.com |
| Phone | 913 942 2300 |
| Currency | USD - US Dollar |
Cingulate Key Financial Ratios
| Return On Equity | -2.76 | ||||
| Gross Profit | (12.1 M) | ||||
| EBITDA | (14.89 M) | ||||
| Net Income | (15.55 M) | ||||
| Cash Per Share | 0.73 X |
Cingulate Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 22.9M | 11.4M | 3.5M | 14.9M | 17.1M | 11.7M | |
| Other Current Liab | (15.1K) | 894.6K | 1.5M | 839.6K | 965.6K | 890.1K | |
| Net Debt | (15.3M) | 509.8K | 3.5M | (7.1M) | (6.4M) | (6.1M) | |
| Accounts Payable | 264.7K | 762.4K | 5.2M | 1.3M | 1.5M | 1.9M | |
| Cash | 16.5M | 5.4M | 52.4K | 12.2M | 14.0M | 14.7M | |
| Net Receivables | 690.2K | 234.4K | 14.6K | 26.3K | 23.7K | 22.5K | |
| Other Current Assets | 1.7M | 2.2M | 511.6K | 423.2K | 486.6K | 462.3K | |
| Total Liab | 2.0M | 7.5M | 10.4M | 7.4M | 8.5M | 6.7M | |
| Net Invested Capital | 20.8M | 8.9M | (3.9M) | 12.4M | 14.3M | 7.5M | |
| Total Current Assets | 18.9M | 7.9M | 578.6K | 12.7M | 14.6M | 7.8M | |
| Net Working Capital | 17.7M | 856.9K | (9.6M) | 7.7M | 8.8M | 9.3M | |
| Short Term Debt | 325.8K | 5.4M | 3.4M | 2.7M | 3.1M | 2.4M | |
| Common Stock | 1.1K | 61.0 | 10.0 | 340.0 | 306.0 | 290.7 | |
| Retained Earnings | (51.7M) | (69.4M) | (92.9M) | (108.5M) | (97.6M) | (102.5M) |
Cingulate Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Net Interest Income | (30.6K) | (174.5K) | (768.2K) | 99.2K | 89.3K | 93.8K | |
| Interest Expense | 33.4K | 174K | 776K | 99K | 113.9K | 208.5K | |
| Gross Profit | (808.4K) | (622.0K) | (582.9K) | (653.1K) | (587.8K) | (617.2K) | |
| Operating Income | (20.7M) | (17.5M) | (22.8M) | (15.6M) | (14.1M) | (14.8M) | |
| Ebit | (20.7M) | (17.5M) | (23.5M) | (15.5M) | (14.0M) | (14.7M) | |
| Research Development | 8.4M | 9.0M | 15.5M | 9.4M | 10.9M | 10.4M | |
| Ebitda | (19.9M) | (17.1M) | (23.0M) | (14.9M) | (13.4M) | (14.1M) | |
| Cost Of Revenue | 808.4K | 622.0K | 582.9K | 653.1K | 751.1K | 676.1K | |
| Income Before Tax | (20.7M) | (17.7M) | (23.5M) | (15.5M) | (14.0M) | (14.7M) | |
| Net Income | (20.7M) | (17.9M) | (23.5M) | (15.5M) | (14.0M) | (14.7M) | |
| Income Tax Expense | 30.5K | 174K | 2.0 | (263.0) | (302.45) | (287.33) |
Cingulate Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (814.7K) | (152.7K) | (180.2K) | (211.8K) | (190.6K) | (181.1K) | |
| Change In Cash | 15.3M | (11.1M) | (5.3M) | 12.2M | 14.0M | 14.7M | |
| Net Borrowings | (936.6K) | 5.0M | 3.0M | 4.9M | 5.7M | 6.0M | |
| Free Cash Flow | (11.2M) | (16.0M) | (15.3M) | (18.7M) | (16.8M) | (17.6M) | |
| Depreciation | 708.3K | 394.0K | 582.9K | 653.1K | 751.1K | 583.6K | |
| Other Non Cash Items | 16.3M | 798.0K | (27.8M) | 995.5K | 895.9K | 940.7K | |
| Capital Expenditures | 814.7K | 153.4K | 224.1K | 211.8K | 190.6K | 376.3K | |
| Net Income | (20.7M) | (17.7M) | (23.5M) | (15.5M) | (14.0M) | (14.7M) | |
| End Period Cash Flow | 16.5M | 5.4M | 52.4K | 12.2M | 14.0M | 14.7M |
Cingulate Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cingulate's current stock value. Our valuation model uses many indicators to compare Cingulate value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cingulate competition to find correlations between indicators driving Cingulate's intrinsic value. More Info.Cingulate is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cingulate's Return On Equity is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cingulate by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Most indicators from Cingulate's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cingulate current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.The Cingulate's current Issuance Of Capital Stock is estimated to increase to about 31.2 M, while Selling General Administrative is projected to decrease to roughly 7.1 M.
| 2023 | 2024 | 2025 | 2026 (projected) | Total Operating Expenses | 22.2M | 15.0M | 17.2M | 16.9M | Cost Of Revenue | 582.9K | 653.1K | 751.1K | 676.1K |
Cingulate fundamental ratios Correlations
Click cells to compare fundamentals
Cingulate Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cingulate fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 22.9M | 11.4M | 3.5M | 14.9M | 17.1M | 11.7M | |
| Other Current Liab | (15.1K) | 894.6K | 1.5M | 839.6K | 965.6K | 890.1K | |
| Net Debt | (15.3M) | 509.8K | 3.5M | (7.1M) | (6.4M) | (6.1M) | |
| Accounts Payable | 264.7K | 762.4K | 5.2M | 1.3M | 1.5M | 1.9M | |
| Cash | 16.5M | 5.4M | 52.4K | 12.2M | 14.0M | 14.7M | |
| Net Receivables | 690.2K | 234.4K | 14.6K | 26.3K | 23.7K | 22.5K | |
| Other Current Assets | 1.7M | 2.2M | 511.6K | 423.2K | 486.6K | 462.3K | |
| Total Liab | 2.0M | 7.5M | 10.4M | 7.4M | 8.5M | 6.7M | |
| Net Invested Capital | 20.8M | 8.9M | (3.9M) | 12.4M | 14.3M | 7.5M | |
| Total Current Assets | 18.9M | 7.9M | 578.6K | 12.7M | 14.6M | 7.8M | |
| Net Working Capital | 17.7M | 856.9K | (9.6M) | 7.7M | 8.8M | 9.3M | |
| Short Term Debt | 325.8K | 5.4M | 3.4M | 2.7M | 3.1M | 2.4M | |
| Common Stock | 1.1K | 61.0 | 10.0 | 340.0 | 306.0 | 290.7 | |
| Retained Earnings | (51.7M) | (69.4M) | (92.9M) | (108.5M) | (97.6M) | (102.5M) |
Today, most investors in Cingulate Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cingulate's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cingulate growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Cingulate January 27, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cingulate help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cingulate. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cingulate based on widely used predictive technical indicators. In general, we focus on analyzing Cingulate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cingulate's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.82 | |||
| Information Ratio | 0.0972 | |||
| Maximum Drawdown | 20.19 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 7.46 |
Complementary Tools for Cingulate Stock analysis
When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |